RelatedPosts
Almost all participants of the experiment for 28 days developed antibodies to the coronavirus.
In China, the company CanSino Biologics has developed a potential vaccine against the coronavirus, which showed a positive result in the test on hundreds of people, reports the Chronicle.info with reference to the Correspondent.
The vaccine is called Ad5-nCoV, she was one of the first vaccines against the coronavirus, which took place early human trials in March.
It is noted that Ad5-nCoV uses a weakened version of a common cold virus known as adenovirus. It infects human cells but does not cause disease — to deliver a fragment of genetic material from the SARS-CoV-2, the virus that causes COVID — 19. The idea is that the human immune system to create antibodies against spinovogo protein, which will help to combat the coronavirus, if the person is later exposed to its effects.
The researchers tested Ad5-nCoV 108 healthy adults aged 18 to 60 years who have not had COVID-19. Participants were given low, medium or high dose of vaccine.
Two weeks after the vaccination, participants of all three groups showed some level of immune response to the virus. After 28 days, almost all of the participants developed antibodies that bind to the SARS-CoV-2 (but not necessarily attack the virus), and about half of the participants in the groups with low and medium dose and three-quarters of participants in the group with high doses produced a “neutralizing antibodies” that bind to and disable the virus to prevent it from infecting cells.
It is noted that among common side effects of Chinese vaccine were mild pain at the injection site, mild fever, fatigue, headache and muscle pain.
While nine participants developed fever to 38.5, and one of the participants in the group with high dose — high temperature along with fatigue, shortness of breath and muscle pain. However, these effects lasted no more than two days.
“These results are an important milestone, but should be interpreted with caution. Problems in the development of a vaccine against COVID-19 unprecedented, and the ability to cause these immune responses do not necessarily indicate that the vaccine will protect people from COVID-19,” said senior author Wei Chen, Beijing Institute of biotechnology in Beijing.
Now researchers have begun a large-scale study of the vaccine of the second phase with the participation of 500 participants who will be assigned to the low or intermediate dose of the vaccine or a placebo. The study also will involve participants over the age of 60, and will be considered side effects within six months after vaccination.
